Skip to main content
. 2015 Oct 2;94(39):e1638. doi: 10.1097/MD.0000000000001638

FIGURE 4.

FIGURE 4

Validation for TIPE2 mRNA as a predictor for 3-month mortality of ACHBLF patients. (A) ROC analysis of the predictive accuracy of TIPE2 mRNA to predict 3-month mortality of ACHBLF in validation cohort. ROC curve for TIPE2 mRNA was 0.912 (SE: 0.0369, 95% CI: 0.814–0.969) and for MELD score 0.717 (SE: 0.0640, 95% CI: 0.590–0.824; P = 0.001). (B) Patients with ACHBLF in validation cohort who had TIPE2 mRNA >6.54 showed significantly poorer survival than those had TIPE2 mRNA ≤6.54 (P < 0.001, log-rank test); (C) ROC curves of TIPE2 mRNA level plus MELD score and MELD score alone; (D) Kaplan–Meier graph showing patients with ACHBLF who had MELD score >24.64 showed significantly poorer survival than those had MELD score ≤24.64 (P < 0.001, log-rank test). ACHBLF = acute-on-chronic hepatitis B liver failure, CI = confidence interval, MELD = model for end-stage liver diseases, ROC = receiver operating characteristic, SE = standard error, TIPE2 = tumor necrosis factor-α-induced protein 8-like 2.